MCLEAN, VA--(Marketwired - May 23, 2016) - Kerecis Omega3 Wound, a fish-skin-based treatment for human tissue repair, is now eligible for Medicare coverage and reimbursement in North Carolina, South Carolina, Virginia and West Virginia. Palmetto GBA, the Medicare administrative contractor for the area, will provide the coverage. The Kerecis fish skin treatment will be considered for coverage as a second-line therapy after regular wound treatment, when there is appropriate documentation of medical necessity.
"This development means that our Omega3 rich fish-skin-based treatment will be available to more Medicare beneficiaries suffering from many types of wounds," said Chris Harte, Chief Operating Officer for Kerecis. "We really appreciate that more U.S. patients will now get the benefits of this innovative treatment and are particularly happy about the coverage in Virginia, our U.S. headquarters," he added.
With the Palmetto GBA coverage, Kerecis Omega3 Wound is now eligible for Medicare coverage and reimbursement in 22 states, the District of Columbia and Puerto Rico. In addition to the United States, the Kerecis product is available in several European and Asian countries, including Germany, Switzerland, Austria, Iceland, Sweden, United Kingdom, Singapore and Thailand.
Kerecis Fish-skin-based Treatment for Chronic Wounds
Kerecis Omega3 is intact fish skin that is rich in naturally occurring Omega3 polyunsaturated fatty acids and is used to regenerate damaged human tissue. When grafted onto damaged human tissue, such as a diabetic ulcer, the acellular material recruits the body's cells from the wound perimeter. These cells are then incorporated into the fish skin, which is ultimately converted into functional, living tissue. The fish skin structure resembles the native structure of human skin. Studies have shown that cells and stem cells proliferate faster in this structure than in other materials such amnion-membrane and other mammalian-sourced materials.
About Kerecis
Kerecis develops regenerative technologies based on fish skin and Omega3 polyunsaturated fatty acids.
The initial Kerecis product, Kerecis Omega3 Wound, has been approved by the FDA and European regulatory authorities for wound healing. The technology is patented in the United States and multiple other countries. The Kerecis wound-healing product has a Medicare "Q" code (Q4158), allowing it to be easily identified and processed by Medicare and private insurance companies.
Production takes place in the Kerecis manufacturing facilities in Iceland. For more information, visit www.kerecis.com. Distributor inquiries are welcome.
Contact Information:
Contact:
Kay Paumier
Communications Plus
408-370-1243